Insmed Inc

1INSM

Company Profile

  • Business description

    Insmed Inc is a biopharmaceutical company. Its commercial portfolio and clinical pipeline are organized around three therapeutic areas: Respiratory, Immunology and Inflammation, and Neuro and Other Rare. The company's two commercial products, Arikayce and Brinsupri, are both part of the Respiratory therapeutic area. The firm's clinical-stage programs are TPIP, INS1148, brensocatib, and INS1201, focusing on different therapeutic areas. Additionally, Insmed's pre-clinical research programs encompass various technologies and modalities, including gene therapy, AI-driven protein engineering, protein manufacturing, RNA end-joining, and synthetic rescue. Geographically, the company generates maximum revenue from the United States from the sale of its commercial products.

  • Contact

    700 US Highway 202/206
    BridgewaterNJ08807
    USA

    T: +1 908 977-9900

    E: [email protected]

    https://www.insmed.com

  • Sector

    Healthcare

    Stock type

    Defensive

  • Industry

    Biotechnology

    Fiscal Year End

    31 December 2026

    Employees

    1,664

Stocks News & Analysis

stocks

ASX utility share downgraded as electricity prices fall

Falling electricity prices weigh on earnings outlook for utility provider.
stocks

Chart of the Week: AI market leader is now surprisingly cheap

This AI beneficiary may still be one of the market’s most compelling bargains.
stocks

Weekly earnings wrap: Rio Tinto leads the way

A closer look at the key earnings results from the first week of August reporting.

Morningstar Investment Ideas

Markets

Index
Last price
Change
% Change
All Ordinaries9,452.0042.100.45%
CAC 408,728.4259.130.68%
DAX 4026,205.4079.100.30%
Dow JONES (US)54,164.51184.61-0.34%
FTSE 10010,883.065.24-0.05%
HKSE25,530.28385.54-1.49%
NASDAQ26,424.6161.170.23%
Nikkei 22565,683.26617.18-0.93%
NZX 50 Index13,958.0639.12-0.28%
S&P 5007,727.523.970.05%
S&P/ASX 2009,271.6041.800.45%
SSE Composite Index3,900.3521.920.57%

Market Movers